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Choosing the culture system and culture medium used to produce cells are key steps towards a safe, scalable 
and cost-effective expansion bioprocess for cell therapy purposes. Traditionally, mesenchymal stromal cells 
(MSC) have been cultured in a defined basal medium (DMEM or alpha-MEM) supplemented with fetal bovine 
serum (FBS). Although effective, the use of FBS or other animal-derived components in manufacturing 
processes is highly discouraged by regulatory agencies due to the risk of transmitting xenogeneic infectious 
agents and immunization. The use of AB human serum (AB HS) as an alternative xeno-free medium 
supplement for MSC has increasingly gained relevance due to safety and efficiency aspects. Here we have 
evaluated different scalable culture systems to produce a meaningful number of umbilical cord matrix-derived 
MSC (UCM MSC) using AB HS for culture medium supplementation during expansion and cryopreservation to 
enable a xeno-free bioprocess. UCM MSC were cultured in a scalable planar (compact 10-layer flasks and roller 
bottles) and 3D microcarrier-based culture systems (spinner flasks and stirred tank bioreactor). 10 layer-flasks 
and roller bottles enabled the production of 2.6±0.6x104 and 1.4±0.3x104 cells/cm2 (4.5±1.1x107 and 3.0±0.7x107 
cells) representing a fold increase of 13.0 and 7.11, respectively. UCM MSC-based microcarrier expansion in 
the stirred conditions has enabled the production of higher cell densities (5.0-23.0x104 cells/cm2) when 
compared to planar systems. Nevertheless, due to the moderate harvest efficiency attained (80% for spinner 
flasks and 53.9% for bioreactor) the total cell number recovered, 3.3-3.7x107 cells, was lower than expected. 
After the expansion in the culture systems evaluated, the cells maintained the functional properties: the cells 
were able to differentiate into adipocytes, chondrocytes and osteocytes and presented a typical 
immunophenotype profile. The cryopreservation of cells (also using AB HS) was also successfully carried out in 
plastic bags to facilitate post-thaw manipulation and enable clinical use. No significant difference was observed 
when comparing pre-cryopreservation and post-thaw viabilities of cells expanded in the planar (T-flasks) and 3D 
culture system (spinner flask with microcarriers) indicating that cells which expanded on a larger scale in 
microcarrier-based suspension cultures could be successfully cryopreserved in plastic bags, with a higher cell 
number (up to 4x108 cells) and under xeno-free conditions. Overall, our results indicated that among the planar 
culture systems evaluated, compact multilayer vessels could be used to easily produce enough cells to treat a 
small number of patients, and are therefore recommended for autologous therapies. However, for a fully-
controlled and larger-scale cell production, in an autologous and/or allogeneic scenario, stirred tank bioreactors 
combined with microcarrier technology and xeno-free media can be successfully used, allowing for GMP-
compliant expansion.     
 
